shutterstock_40412344_-orla

Orla / Shutterstock.com

30 September 2019Big PharmaRory O'Neill

Genetic research: DNA payday

After decades of reliance on blockbuster drugs, pharmaceutical companies are increasingly having to face up to the challenge of diversifying their businesses.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

AbbVie blocks Humira antitrust suit

AstraZeneca suffers defeat over $7bn diabetes patent

American Regent secures rare PI win in Hatch-Waxman dispute

In-house with Bayer: ‘Focus on quality early and stay close to inventors’

Explainer: ARIPO’s role in Plant Variety Protection

J&J sues over schizophrenia drug generic following patent victory

WATCH: The transparency tightrope—balancing innovation, regulation, and IP protection in a new era

J&J fends off generic schizophrenia drug bids